Targeting genomic alterations in squamous cell lung cancer

Frontiers in Oncology

Volumn 3 AUG, Issue , 2013, Pages

  Mantripragada, Kalyan ^a   Khurshid, Humera ^a  

^a Brown University Oncology Group   (United States)

Author keywords

AKT1; DDR2; EML4 ALK; EphA2; FGFR1; LKB1; PIK3CA; SOX2

Indexed keywords

1 TERT BUTYL 3 [6 (3, 5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO) PYRIDO [2, 3 D] PYRIMIDIN 7 YL] UREA; 1 TERT BUTYL 3 [6 (3,5 DIMETHOXYPHENYL) 2 (4 DIETHYLAMINOBUTYLAMINO)PYRIDO[2,3 D]PYRIMIDIN 7 YL]UREA; 4 AMINO N [1 (4 CHLOROPHENYL) 3 HYDROXYPROPYL] 1 (7H PYRROLO [2, 3 D] PYRIMIDIN 4 YL) 4 PIPERIDINECARBOXAMIDE AZD5363; 4 AMINO N [1 (4 CHLOROPHENYL) 3 HYDROXYPROPYL] 1 (7H PYRROLO[2,3 D]PYRIMIDIN 4 YL) 4 PIPERIDINECARBOXAMIDE; 8 [4 (1 AMINOCYCLOBUTYL) PHENYL] 9 PHENYL 1, 2, 4 TRIAZOLO [3, 4 F] [1, 6] NAPHTHYRIDIN 3 (2H) ONE; 8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; ANTINEOPLASTIC AGENT; ARRY 438162; AZD 4547; BUPARLISIB; BYL 719; CARBOPLATIN; CETUXIMAB; CRIZOTINIB; DASATINIB; DOCETAXEL; ERLOTINIB; EVEROLIMUS; FORETINIB; GEFITINIB; GSK 2636771; IMATINIB; IPATASERTIB; MITOGEN ACTIVATED PROTEIN KINASE; NVP BGJ 398; PACLITAXEL; RABEPRAZOLE; RAPAMYCIN; RIDAFOROLIMUS; SAR 245409; SAR 256212; UNCLASSIFIED DRUG; UNINDEXED DRUG; VADIMEZAN; X 396;

CANCER SURVIVAL; CELL VIABILITY; DRUG DOSE INCREASE; DRUG SAFETY; DRUG TOLERABILITY; GENE AMPLIFICATION; GENE MUTATION; GENETIC VARIABILITY; GENOMIC ALTERATION; HUMAN; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SQUAMOUS CELL CARCINOMA; LUNG TOXICITY; MOLECULAR GENETICS; MUCOSA INFLAMMATION; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLEURA EFFUSION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH;

EID: 84891052227     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00195     Document Type: Review

References (86)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin (2013) 63:11-30. doi:10.3322/caac.21166
2. Morgensztern D, Waqar S, Subramanian J, Gao F, Govindan R. Improving survival for stage IV non-small cell lung cancer: a surveillance, epidemiology, and end results survey from 1990 to 2005. J Thorac Oncol (2009) 4:1524-9. doi:10.1097/JTO.0b013e3181ba3634
3. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med (2010) 363:1693-703. doi:10.1056/NEJMoa1006448
4. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol (2011) 12:1004-12. doi:10.1016/S1470-2045(11)70232-7
5. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 101:13306-11. doi:10.1073/pnas.0405220101
6. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 350:2129-39. doi:10.1056/NEJMoa040938
7. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol (2011) 12:735-42. doi:10.1016/S1470-2045(11)70184-X
8. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol (2012) 13:239-46.
9. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med (2009) 361:947-57. doi:10.1056/NEJMoa0810699
10. Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, et al. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J Clin Oncol (2011) 29:2866-74. doi:10.1200/JCO.2010.33.4235
11. Felip E, Gridelli C, Baas P, Rosell R, Stahel R, Panel Members. Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010. Ann Oncol (2011) 22:1507-19. doi:10.1093/annonc/mdr150
12. Ju YS, Lee WC, Shin JY, Lee S, Bleazard T, Won JK, et al. A transforming KIF5B and RET gene fusion in lung adenocarcinoma revealed from whole-genome and transcriptome sequencing. Genome Res (2012) 22:436-45. doi:10.1101/gr.133645.111
13. Rekhtman N, Paik PK, Arcila ME, Tafe LJ, Oxnard GR, Moreira AL, et al. Clarifying the spectrum of driver oncogene mutations in biomarker-verified squamous carcinoma of lung: lack of EGFR/KRAS and presence of PIK3CA/AKT1 mutations. Clin Cancer Res (2012) 18:1167-76. doi:10.1158/1078-0432.CCR-11-2109
14. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 489:519-25. doi:10.1038/nature11404
15. Ichikawa O, Osawa M, Nishida N, Goshima N, Nomura N, Shimada I. Structural basis of the collagen-binding mode of discoidin domain receptor 2. EMBO J (2007) 26:4168-76. doi:10.1038/sj.emboj.7601833
16. Ruiz PA, Jarai G. Collagen I induces discoidin domain receptor (DDR) 1 expression through DDR2 and a JAK2-ERK1/2-mediated mechanism in primary human lung fibroblasts. J Biol Chem (2011) 286:12912-23. doi:10.1074/jbc.M110.143693
17. Vogel WF, Abdulhussein R, Ford CE. Sensing extracellular matrix: an update on discoidin domain receptor function. Cell Signal (2006) 18:1108-16. doi:10.1016/j.cellsig.2006.02.012
18. Hammerman PS, Sos ML, Ramos AH, Xu C, Dutt A, Zhou W, et al. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 1:78-89. doi:10.1158/2159-8274.CD-11-0005
19. Day E, Waters B, Spiegel K, Alnadaf T, Manley PW, Buchdunger E, et al. Inhibition of collagen-induced discoidin domain receptor 1 and 2 activation by imatinib, nilotinib and dasatinib. Eur J Pharmacol (2008) 599:44-53. doi:10.1016/j.ejphar.2008.10.014
20. Haura EB, Tanvetyanon T, Chiappori A, Williams C, Simon G, Antonia S, et al. Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer. J Clin Oncol (2010) 28:1387-94. doi:10.1200/JCO.2009.25.4029
21. Khurshid H, Dipetrillo T, Ng T, Mantripragada K, Birnbaum A, Berz D, et al. A phase I study of dasatinib with concurrent chemoradiation for stage III non-small cell lung cancer. Front Oncol (2012) 2:56. doi:10.3389/fonc.2012.00056
22. Yamamoto H, Shigematsu H, Nomura M, Lockwood WW, Sato M, Okumura N, et al. PIK3CA mutations and copy number gains in human lung cancers. Cancer Res (2008) 68:6913-21. doi:10.1158/0008-5472.CAN-07-5084
23. Spoerke JM, O'Brien C, Huw L, Koeppen H, Fridlyand J, Brachmann RK, et al. Phosphoinositide 3-kinase (PI3K) pathway alterations are associated with histologic subtypes and are predictive of sensitivity to PI3K inhibitors in lung cancer preclinical models. Clin Cancer Res (2012) 18:6771-83. doi:10.1158/1078-0432.CCR-12-2347
24. Kawano O, Sasaki H, Endo K, Suzuki E, Haneda H, Yukiue H, et al. PIK3CA mutation status in Japanese lung cancer patients. Lung Cancer (2006) 54:209-15. doi:10.1016/j.lungcan.2006.07.006
25. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science (1997) 275:1943-7. doi:10.1126/science.275.5308.1943
26. Knobbe CB, Reifenberger G. Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3'-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol (2003) 13:507-18. doi:10.1111/j.1750-3639.2003.tb00481.x
27. Okudela K, Suzuki M, Kageyama S, Bunai T, Nagura K, Igarashi H, et al. PIK3CA mutation and amplification in human lung cancer. Pathol Int (2007) 57:664-71. doi:10.1111/j.1440-1827.2007.02155.x
28. Ji M, Guan H, Gao C, Shi B, Hou P. Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). BMC Cancer (2011) 11:147. doi:10.1186/1471-2407-11-147
29. Sun Y, Ren Y, Fang Z, Li C, Fang R, Gao B, et al. Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases. J Clin Oncol (2010) 28:4616-20. doi:10.1200/JCO.2010.29.6038
30. Engelman JA, Mukohara T, Zejnullahu K, Lifshits E, Borrás AM, Gale CM, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer. J Clin Invest (2006) 116:2695-706. doi:10.1172/JCI28656
31. Sequist LV, Waltman BA, Dias-Santagata D, Digumarthy S, Turke AB, Fidias P, et al. Genotypic and histologic evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 3:75ra26. doi:10.1126/scitranslmed.3002003
32. Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, et al. Phase I, dose-escalation study of [1], an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol (2012) 30:282-90. doi:10.1200/JCO.2011.36.1360
33. Zou ZQ, Zhang XH, Wang F, Shen QJ, Xu J, Zhang LN, et al. A novel dual PI3Kalpha/mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells. Int J Mol Med (2009) 24:97-101.
34. Davidson L, MacCario H, Perera NM, Yang X, Spinelli L, Tibarewal P, et al. Suppression of cellular proliferation and invasion by the concerted lipid and protein phosphatase activities of PTEN. Oncogene (2010) 29:687-97. doi:10.1038/onc.2009.384
35. Jin G, Kim MJ, Jeon HS, Choi JE, Kim DS, Lee EB, et al. PTEN mutations and relationship to EGFR, ERBB2, KRAS, and TP53 mutations in non-small cell lung cancers. Lung Cancer (2010) 69:279-83. doi:10.1016/j.lungcan.2009.11.012
36. Lee SY, Kim MJ, Jin G, Yoo SS, Park JY, Choi JE, et al. Somatic mutations in epidermal growth factor receptor signaling pathway genes in non-small cell lung cancers. J Thorac Oncol (2010) 5:1734-40. doi:10.1097/JTO.0b013e3181f0beca
37. Sos ML, Koker M, Weir BA, Heynck S, Rabinovsky R, Zander T, et al. PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR. Cancer Res (2009) 69:3256-61. doi:10.1158/0008-5472.CAN-08-4055
38. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, et al. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A (2001) 98:10314-9. doi:10.1073/pnas.171076798
39. Andjelkovic M, Alessi DR, Meier R, Fernandez A, Lamb NJ, Frech M, et al. Role of translocation in the activation and function of protein kinase B. J Biol Chem (1997) 272:31515-24. doi:10.1074/jbc.272.50.31515
40. Bellacosa A, Chan TO, Ahmed NN, Datta K, Malstrom S, Stokoe D, et al. Akt activation by growth factors is a multiple-step process: the role of the PH domain. Oncogene (1998) 17:313-25. doi:10.1038/sj.onc.1201947
41. Stokoe D, Stephens LR, Copeland T, Gaffney PR, Reese CB, Painter GF, et al. Dual role of phosphatidylinositol-3,4,5-trisphosphate in the activation of protein kinase B. Science (1997) 277:567-70. doi:10.1126/science.277.5325.567
42. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer (2002) 2:489-501. doi:10.1038/nrc839
43. Vanhaesebroeck B, Alessi DR. The PI3K-PDK1 connection: more than just a road to PKB. Biochem J (2000) 346:561-76. doi:10.1042/0264-6021:3460561
44. Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, et al. A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature (2007) 448:439-44. doi:10.1038/nature05933
45. Do H, Solomon B, Mitchell PL, Fox SB, Dobrovic A. Detection of the transforming AKT1 mutation E17K in non-small cell lung cancer by high resolution melting. BMC Res Notes (2008) 1:14. doi:10.1186/1756-0500-1-14
46. Malanga D, Scrima M, De Marco C, Fabiani F, De Rosa N, De Gisi S, et al. Activating E17K mutation in the gene encoding the protein kinase AKT1 in a subset of squamous cell carcinoma of the lung. Cell Cycle (2008) 7:665-9. doi:10.4161/cc.7.5.5485
47. Saura C, Jones S, Mateo J, Hollebecque A, Cleary JM, Roda Perez D, et al. A phase Ib study of the Akt inhibitor GDC-0068 with docetaxel (D) or mFOLFOX-6 (F) in patients (pts) with advanced solid tumors. J Clin Oncol (2012) 30:3021.
48. Pasquale EB. Eph receptor signaling casts a wide net on cell behavior. Nat Rev Mol Cell Biol (2005) 6:462-75. doi:10.1038/nrm1690
49. Brannan JM, Dong W, Prudkin L, Behrens C, Lotan R, Bekele BN, et al. Expression of the receptor tyrosine kinase EphA2 is increased in smokers and predicts poor survival in non small cell lung cancer. Clin Cancer Res (2009) 15:4423-30. doi:10.1158/1078-0432.CCR-09-0473
50. Faoro L, Singleton PA, Cervantes GM, Lennon FE, Choong NW, Kanteti R, et al. EphA2 mutation in lung squamous cell cancer promotes increased cell survival, cell invasion, focal adhesion, and mammalian target of rapamycin activation. J Biol Chem (2010) 285:18575-85. doi:10.1074/jbc.M109.075085
51. Lombardo LJ, Lee FY, Chen P, Norris D, Barrish JC, Behnia K, et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem (2004) 47:6658-61. doi:10.1021/jm049486a
52. Chang Q, Jorgensen C, Pawson T, Hedley DW. Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br J Cancer (2008) 99:1074-82. doi:10.1038/sj.bjc.6604676
53. Shah U, Sharpless NE, Hayes DN. LKB1 and lung cancer: more than the usual suspects. Cancer Res (2008) 68:3562-5. doi:10.1158/0008-5472.CAN-07-6620
54. Ghaffar H, Sahin F, Sanchez-Cepedes M, Su GH, Zahurak M, Sidransky D, et al. LKB1 protein expression in the evolution of glandular neoplasia of the lung. Clin Cancer Res (2003) 9:2998-3003.
55. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P, et al. LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 448:807-10. doi:10.1038/nature06030
56. Yilmaz E, Averett L, Diao BL, Giri U, Gudikote J, Fan YH, et al. Use of proteomic analysis of LKB1/AMPK/mTOR pathways to identify IGF-1R pathway upregulation with LKB1 loss or mTOR inhibition in NSCLC: Implications for targeted combinations. J Clin Oncol (2012) 30:10612.
57. Dutt A, Ramos AH, Hammerman PS, Mermel C, Cho J, Sharifnia T, et al. Inhibitor-sensitive FGFR1 amplification in human non-small cell lung cancer. PLoS ONE (2011) 6:e20351. doi:10.1371/journal.pone.0020351
58. Weiss J, Sos ML, Seidel D, Peifer M, Zander T, Heuckmann JM, et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci Transl Med (2010) 2:62ra93. doi:10.1126/scitranslmed.3001451
59. Göke F, Franzen A, Menon R, Goltz D, Kirsten R, Boehm D, et al. Rationale for treatment of metastatic squamous cell carcinoma of the lung using fibroblast growth factor receptor inhibitors. Chest (2012) 142:1020-6. doi:10.1378/chest.11-2943
60. Turner NC, Seckl MJ. A therapeutic target for smoking-associated lung cancer. Sci Transl Med (2010) 2:62s56. doi:10.1126/scitranslmed.3001942
61. Guagnano V, Kauffmann A, Wohrle S, Stamm C, Ito M, Barys L, et al. FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor. Cancer Discov (2012) 2:1118-33. doi:10.1158/2159-8290.CD-12-0210
62. Wolf J, LoRusso PM, Camidge RD, Perez JM, Tabernero J, Hidalgo M, et al. A phase I dose escalation study of NVP-BGJ398, a selective pan FGFR inhibitor in genetically preselected advanced solid tumors. Cancer Res (2012) 72:LB122. doi:10.1158/1538-7445.AM2012-LB-122
63. Que J, Luo X, Schwartz RJ, Hogan BL. Multiple roles for Sox2 in the developing and adult mouse trachea. Development (2009) 136:1899-907. doi:10.1242/dev.034629
64. Gontan C, de Munck A, Vermeij M, Grosveld F, Tibboel D, Rottier R. Sox2 is important for two crucial processes in lung development: branching morphogenesis and epithelial cell differentiation. Dev Biol (2008) 317:296-309. doi:10.1016/j.ydbio.2008.02.035
65. Garraway L, Sellers W. Lineage dependency and lineage-survival oncogenes in human cancer. Nat Rev Cancer (2006) 6:593-602. doi:10.1038/nrc1972
66. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 41:1238-42. doi:10.1038/ng.465
67. Hussenet T, Dali S, Exinger J, Monga B, Jost B, Dembele D, et al. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS ONE (2010) 5:e8960. doi:10.1371/journal.pone.0008960
68. Sholl LM, Long KB, Hornick JL. Sox2 expression in pulmonary non-small cell and neuroendocrine carcinomas. Appl Immunohistochem Mol Morphol (2010) 18:55-61. doi:10.1097/PAI.0b013e3181b16b88
69. Lu Y, Futtner C, Rock JR, Xu X, Whitworth W, Hogan BL, et al. Evidence that SOX2 overexpression is oncogenic in the lung. PLoS ONE (2010) 5:e11022. doi:10.1371/journal.pone.0011022
70. Cooper CS, Park M, Blair DG, Tainsky MA, Huebner K, Croce CM, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature (1984) 311:29-33. doi:10.1038/311029a0
71. Furge KA, Zhang YW, Vande Woude GF. Met receptor tyrosine kinase: enhanced signaling through adapter proteins. Oncogene (2000) 19:5582-9. doi:10.1038/sj.onc.1203859
72. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol (2003) 4:915-25. doi:10.1038/nrm1261
73. Rubin JS, Chan AM, Bottaro DP, Burgess WH, Taylor WG, Cech AC, et al. A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor. Proc Natl Acad Sci U S A (1991) 88:415-9. doi:10.1073/pnas.88.2.415
74. Bussolino F, Di Renzo MF, Ziche M, Bocchietto E, Olivero M, Naldini L, et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J Cell Biol (1992) 119:629-41. doi:10.1083/jcb.119.3.629
75. Giordano S, Corso S, Conrotto P, Artigiani S, Gilestro G, Barberis D, et al. The semaphorin 4D receptor controls invasive growth by coupling with Met. Nat Cell Biol (2002) 4:720-4. doi:10.1038/ncb843
76. Benvenuti S, Comoglio PM. The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol (2007) 213:316-25. doi:10.1002/jcp.21183
77. Rong S, Segal S, Anver M, Resau JH, Vande Woude GF. Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci U S A (1994) 91:4731-5. doi:10.1073/pnas.91.11.4731
78. Lutterbach B, Zeng Q, Davis LJ, Hatch H, Hang G, Kohl NE, et al. Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res (2007) 67:2081-8. doi:10.1158/0008-5472.CAN-06-3495
79. Schmidt L, Duh FM, Chen F, Kishida T, Glenn G, Choyke P, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat Genet (1997) 16:68-73. doi:10.1038/ng0597-68
80. Kong-Beltran M, Seshagiri S, Zha J, Zhu W, Bhawe K, Mendoza N, et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res (2006) 66:283-9. doi:10.1158/0008-5472.CAN-05-2749
81. Cai YR, Zhang HQ, Qu Y, Mu J, Zhao D, Zhou LJ, et al. Expression of MET and SOX2 genes in non-small cell lung carcinoma with EGFR mutation. Oncol Rep (2011) 26:877-85. doi:10.3892/or.2011.1349
82. Cappuzzo F, Janne PA, Skokan M, Finocchiaro G, Rossi E, Ligorio C, et al. MET increased gene copy number and primary resistance to gefitinib therapy in non-small-cell lung cancer patients. Ann Oncol (2009) 20:298-304. doi:10.1093/annonc/mdn635
83. Benedettini E, Sholl LM, Peyton M, Reilly J, Ware C, Davis L, et al. Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol (2010) 177:415-23. doi:10.2353/ajpath.2010.090863
84. Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, et al. Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol (2011) 6:942-6. doi:10.1097/JTO.0b013e31821528d3
85. Spigel DR, Ervin TJ, Ramlau R, Daniel DB, Goldschmidt JH, Blumenschein GR, et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. J Clin Oncol (2011) 29:7505.
86. Seo JS, Ju YS, Lee WC, Shin JY, Lee JK, Bleazard T, et al. The transcriptional landscape and mutational profile of lung adenocarcinoma. Genome Res (2012) 22:2109-19. doi:10.1101/gr.145144.112